Local immunosuppressive damage in the human papillomavirus persistence 
A.G. Kedrova
Institute for Advanced Training of Federal Medical Biological Agency, Moscow

The incidence rate of cervical cancer in Russia is 13-15 cases per 100 thousand of people, which causes the urgency of discussing the problem of improving prevention and early diagnosis of precancer and cervical cancer. The persistence of oncogenic types of human papillomavirus (HPV) predisposes to the development of cervical cancer. In most people, HPV infection is asymptomatic and in more than 90% of cases it can be reduced on its own within 1-2 years. Lesions that have not been eliminated by the immune system can persist for several decades, leading to the integration of viral proteins into the cell genome and the development of cancer. The article considers the possibilities of using the immunomodulator inosine pranobex in the treatment of HPV. The advantage of the drug over the other immunomodulators is that it effects on various parts of the immune system and normalizes the functional abilities of the cells. It’s direct antiviral effect allows reducing the viral load, which, while simultaneously normalizing the functional activity of macrophages, leads to an increase in the elimination of papillomavirus infection. The authors present the data of their own studies that demonstrate the effectiveness of inosine pranobex which depends on the duration of the course and under the 28-day regimen allows to achieve virus elimination in 72.4% of patients for 6 months.

Key words: mild cervical dysplasia, low-grade intraepithelial lesions, inosine pranobex, papillomavirus infection, cervical cancer.
For citation: Kedrova A.G. Local immunosuppressive damage in the human papillomavirus persistence // RMJ. 2017. № 26. P. 1971–1976.